Sign in to view content

Brolucizumab in HAWK/HARRIER: Outcomes, Efficacy, & Dosing Status – Everything You Need to Know!

David M. Brown, MD

Video
Published 2018

Related

Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022
Journal Club with Dr. Ferhina Ali and Dr. Daniel Chao Discussing Caffeine and Beta Blockers for Vitreoretinal Surgeons, Cost-Savings with Intravitreal Bevacizumab, and more
Jayanth Sridhar, MD
Daniel L Chao, MD, PhD
Ferhina S Ali, MD, MPH
Member Podcasts
2020
Anti-VEGF Injection Prior Authorization Impacts on Retina Practices
Sabin Dang, MD
Updates from the Field
2022

Category: AMD-Neovascular

See more